Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Tafasitamab in Combination with a CD20xCD3 Bispecific T-Cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models

Eveline Schaadt, Christina Heitmüller, Solveig Peters, Kristina Ilieva, Derek Blair, Christiane Huth, Dominik Bartel, Sandra Zapf, Markus Eberl, Doris Mangelberger-Eberl, Frank Giles, Carsten Corvey

Blood (2023) 142 (Supplement 1): 2813.

https://doi.org/10.1182/blood-2023-188574

Published: 2023

Journal Articles

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín Garcia-Gutiérrez, Henrik Hjorth-Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gerald Luscan, Andrea Viqueira, Frank Giles, Andreas Hochhaus

Blood (2021) 138 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2021-150352

Published: 2021

Journal Articles

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Carlo Gambacorti-Passerini, MD, Tim H Brümmendorf, MD, Bjorn T. Gjertsen, MD PhD, Camille Abboud, MD, Gianantonio Rosti, MD, Elisabetta Abruzzese, MD, Eric Leip, PhD, Andrea Viqueira, MD, Valentín García Gutiérrez, PhD, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 2936.

https://doi.org/10.1182/blood-2019-121813

Published: 2019

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Tim H Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Camille Abboud, MD, Justin M. Watts, MD, Gianantonio Rosti, MD, Alexander Russell-Smith, Andrea Viqueira, MD, Arlene Reisman, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 4157.

https://doi.org/10.1182/blood-2019-124344

Published: 2019

Journal Articles

Indoleamine 2,3-Dioxygenase (IDO1) Levels and Activity Are Increased in Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Correlate with Molecular Response to Nilotinib Therapy

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Gunther Gastl, Prof., Dr., Zlatko Trajanoski, Prof. Dr., Frank Giles, MD MB, Andreas Hochhaus, MD, Simon Geisler, Dietmar Fuchs, Prof. Dr., Dominik Wolf, MD, Jeroen J.W.M. Janssen, MD PhD

Blood (2016) 128 (22): 1912.

https://doi.org/10.1182/blood.V128.22.1912.1912

Published: 2016

Journal Articles

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Michael Cross, PhD, Oliver Frank, PhD, Frank Giles, MDMB, Andreas Hochhaus, MD, Christian T. Dietz, PhD, Martin C. Müller, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2015) 126 (23): 135.

https://doi.org/10.1182/blood.V126.23.135.135

Published: 2015

Journal Articles

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Blood (2015) 126 (23): 4022.

https://doi.org/10.1182/blood.V126.23.4022.4022

Published: 2015

Journal Articles

Increased TACE (Tumor necrosis factor-alpha±-converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results from an ENEST1st Substudy

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Angelica Loskog, PhD, Bjorn T. Gjertsen, MD PhD, Guenther A. Gastl, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Gert J. Ossenkoppele, MD PhD, Kimmo Porkka, MD PhD, Dominik Wolf, MD

Blood (2015) 126 (23): 4033.

https://doi.org/10.1182/blood.V126.23.4033.4033

Published: 2015

Journal Articles

Synthetic High-Density Lipoprotein-like Nanoparticles (HDL NP) Cause Apoptosis and Enhance Killing By B-Cell Receptor and BCL-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Kaylin Marie McMahon, Cristina Scielzo, Lydia Scarfo, Pamela Ranghetti, Shuo Yang, Leo I. Gordon, MD, Frank Giles, MDMB, Colby Shad Thaxton, MD PhD, Paolo Ghia, MD PhD

Blood (2015) 126 (23): 2949.

https://doi.org/10.1182/blood.V126.23.2949.2949

Published: 2015

Journal Articles

GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis

Philippe Guardiola, MD, Corentin Orvain, Nick C.P. Cross, PhD, Martine Gardembas, MD, Marc Spentchian, MD, Estelle Pedrono, PhD, Diane Lambert, PhD, Anne Coutolleau, Anne Bouvier, MD, Odile Blanchet, MDPhD, Nicole Piard, MD, Norbert Ifrah, MD PhD, Frank Giles, MD MB, FRCPI, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, Philippe Rousselot, MD PhD

Blood (2015) 126 (23): 2768.

https://doi.org/10.1182/blood.V126.23.2768.2768

Published: 2015

Journal Articles

Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib

Blood (2015) 126 (23): 1570.

https://doi.org/10.1182/blood.V126.23.1570.1570

Published: 2015

Journal Articles

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Frank Giles, MD MB, FRCPI, FRCPath, Sarina A. Piha-Paul, MD, Alexander I. Spira, PhD MD FACP, Fadi Braiteh, MD CPI, Julio Antonio Peguero, MD, Daniel L. Spitz, MD FACP, James A. Knost, MD, Lee Schwartzberg, MD FACP, Steven Stein, MD, August J. Salvado, MD, Claudia Lebedinsky, MD, Barinder Kang, PhD, Eric Slosberg, PhD

Blood (2014) 124 (21): 4818.

https://doi.org/10.1182/blood.V124.21.4818.4818

Published: 2014

Journal Articles

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Karoline Schubert, Michael Cross, PhD, Sabine Leiblein, Kathrin Wildenberger, Frank Giles, MDMB, Andreas Hochhaus, MD, Oliver Frank, PhD, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2014) 124 (21): 3143.

https://doi.org/10.1182/blood.V124.21.3143.3143

Published: 2014

Journal Articles

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Christian Dietz, PhD, Michael Lauseker, PhD, Benjamin Hanfstein, MD, Philippe Rousselot, MD, Thoralf Lange, MD, Jacqueline Maier, PhD, Letizia Foroni, Gareth Gerrard, Rodica Talmaci, PhD, Jeroen JWM Janssen, MD, Oliver Frank, PhD, Susanne Saussele, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2014) 124 (21): 3144.

https://doi.org/10.1182/blood.V124.21.3144.3144

Published: 2014

Journal Articles

Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Angelica Loskog, PhD, Bjorn T. Gjertsen, MD PhD, Ute Mark, Jens Haenig, Nidas Jurjonas, Gunther Gastl, Prof., Dr., Frank Giles, MDMB, Andreas Hochhaus, MD, Gert J Ossenkoppele, MD PhD, Kimmo Porkka, MD PhD, Dominik Wolf, MD

Blood (2014) 124 (21): 4522.

https://doi.org/10.1182/blood.V124.21.4522.4522

Published: 2014

Journal Articles

Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Blood (2013) 122 (21): 2731.

https://doi.org/10.1182/blood.V122.21.2731.2731

Published: 2013

Journal Articles

Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Blood (2013) 122 (21): 1485.

https://doi.org/10.1182/blood.V122.21.1485.1485

Published: 2013

Journal Articles

Telomere Shortening At Diagnosis Of Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Is Significantly More Pronounced In Patients With Less-Than-Optimal Versus Optimal Molecular Response (ELN criteria) After 12 Months Of Treatment With Nilotinib

Katrin Wenn, Lena Tomala, Fabian Beier, MD, Stefan Wilop, MD, Lucia Vankann, Christian Hasenbank, Oliver Frank, Claudia Walasek, Andreas Hochhaus, MD, Frank Giles, MD MB, Steffen Koschmieder, Patrick Ziegler, PhD, Tim H. Brümmendorf, MD

Blood (2013) 122 (21): 1471.

https://doi.org/10.1182/blood.V122.21.1471.1471

Published: 2013

NARROW

Tafasitamab in Combination with a CD20xCD3 Bispecific T-Cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Indoleamine 2,3-Dioxygenase (IDO1) Levels and Activity Are Increased in Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Correlate with Molecular Response to Nilotinib Therapy

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Synthetic High-Density Lipoprotein-like Nanoparticles (HDL NP) Cause Apoptosis and Enhance Killing By B-Cell Receptor and BCL-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL)

GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis

Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Telomere Shortening At Diagnosis Of Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Is Significantly More Pronounced In Patients With Less-Than-Optimal Versus Optimal Molecular Response (ELN criteria) After 12 Months Of Treatment With Nilotinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only